Get started

Pharmaceuticals

Ahrvo Daily Movers: Horizon Therapeutics-Bullish on this BiotechAbout Horizon Therapeutics Horizon Therapeutics(ticker: HZNP) is a biopharmaceutical company that focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. HZNP was founded in 2005 and is headquartered in Dublin, Ireland. Ahrvo Stock Rankings Horizon Therapeutics is a top-ten ranked stock on Ahrvo, coming in 6th place (out of over 7,000+ stocks we cover) based on the most recent daily rankings. HZNP has an AhrvoScore (overall score) of 99. Over the last 3 months, Horizon has seen a slight increase in AhrvoScore, up 2 points. Momentum Score, Quality Score, Value Score, and Growth Score are top-notch, clocking in at 94, 80, 99, and 99, respectively. All four sub-scores have increased over the last 3 months. Momentum is up 5 points, Quality up 1 point, Value up 5 points, and Growth up 2 points. Furthermore, Horizon Therapeutics ranks higher than its competitors across all stock scores: Ahrvo Score 99 vs. 35, Momentum Score 94 vs. 62, Value Score 99 vs. 14, Quality Score 80 vs. 18, and Growth Score 99 vs. 42. Ahrvo’s proprietary trading signal also indicates that HZNP is currently a STRONG BUY. Our Take Horizon Therapeutics has performed well relative to the S&P 500 (ticker: SPY) and Nasdaq Biotechnology Index (ticker: IBB). Over the last 6 months, HZNP is up +21%, while the S&P 500 and Biotech Index have returned -8% and +10%, respectively. The company is extremely profitable with net margins of 44%. Last year they earned $573 million on $1.3 billion in revenue. Horizon Therapeutics reports Q1 earnings on Wednesday and is expected to beat analyst expectations. HZNP’s orphan drug portfolio should remain resilient and continue to perform well in the face of economic uncertainty. Orphan drugs are created for extremely rare diseases and drug recipients will need HZNP’s remedies irregardless of what happens with the broader economy. The analyst community is positive on the stock as well. Out of the 12 analysts that cover the company, 10 have HZNP rated as a strong buy (3) or buy (7), with 2 holds. Horizon Therapeutics 12-month median price target is $44.60, representing 25% upside from current levels. -Appo Agbamu, CFA This material is for informational purposes only. Under no circumstances should any information or materials presented be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. Any investment made is at your sole discretion. There are many factors that you must consider when making an investment decision, including, but not limited to, product features, risks, whether or not an investment meets your investment objectives, risk tolerance, and other personalized factors. Investing in securities involves risks, and there is always the potential of losing your entire investment.
HLong
by AhrvoStockApp
MJ Trending UpETFMG Alternative Harvest (NYSE: MJ ) What is ETFMG Alternative Harvest? An ETF that acceptance of various uses of the cannabis plant such as pharmaceuticals, biotechnology and life sciences, JesusTrade Score: Buy Scale Score: Low (3/10) Portfolio Hold: Yearly Hold Fundamental Reasoning: The following below are the top 10 holding for MJ: GW Pharmaceuticals PLC Sponsored ADR (GWPH) Aphria Inc (APHA) Aurora Cannabis Inc. (ACB) MediPharm Labs Corp. (MEDIF) Cronos Group Inc (CRON) Corbus Pharmaceuticals Holdings Inc (CRBP) OrganiGram Holdings Inc (OGI) Canopy Growth Corporation (CGC) Tilray, Inc. (TLRY) Swedish Match AB (SWMAF) All of these but Tilray and Swedish Match have bullish diverange and have broke out. Tilray could just follow the hype of the other stocks and Swedish Match has been having an up trend since March of 2009 and has about $30 more to run. With mojirty of these stocks being worth less than $10 or even $5. I don't see why the volume wouldn't be coming in. On google trends there an increase of cannabis and cannabis companies being searched. which gives me a idea that new buyers could be coming.
AMEX:MJLong
by Jesus_Trade
It's hard to overstate how important the NVAX Phase 3 result isNovavax's Nanoflu isn't your typical new drug-- it's a whole new pharmaceutical technology. So it's hard to overstate how important today's positive Phase 3 clinical trial result is. Positive Phase 3 trial data this morning suggest that Novavax's Virus-Like Particle (VLP)-based flu vaccines will be much more effective than existing egg-based vaccines. When you make a vaccine in an egg, it can mutate in the egg and no longer match the flu strains it's supposed to prevent. The VLP vaccines, by contrast, are genetically identical to the targeted flu strains. This increases the vaccines' effectiveness against the targeted strains. Nanoflu also includes something called "adjuvant Matrix-M," which increases the number of antibodies produced in response to the vaccine by something on the order of 50%. Stronger immune response means greater effectiveness, though it also modestly increased the incidence of adverse events in Novavax's trial. One particular important result from the Phase 3 trial was that Nanoflu was more effective than its competitors against A/H3N2, the most lethal family of flu viruses and the one against which vaccines have traditionally been least effective. I have some friends doing work in this field, and they've told me that there are three really exciting things about these VLP vaccines: 1) they aren't infectious, which makes them safer than using an attenuated virus, 2) they protect against not only the strain of virus they target, but also some mutant forms of it, and 3) they take 12 weeks to produce rather than the traditional 9 months. This last point is the real game-changer. Imagine being able to get vaccines to market in a third of the traditional time. Novavax is also working on a VLP-based Covid-19 vaccine. We can probably expect the FDA to rush approval of both Nanoflu and the CoV-19 vaccine.
NASDAQ:NVAXLong
by ChristopherCarrollSmith
5
BMY is worth buyingBristol-Myers Squibb says it has seen no major business disruptions and expects no decrease in global demand for its drugs this year. That means the 3.5% dividend yield should stay stable, and BMY is a great value at 1.3 PEG. BMY also just got FDA approval for a multiple sclerosis drug, which could turn out to be a pretty big deal. Most of the market has been trading based on macroeconomics, but as individual companies like BMY issue quantitative guidance, I think we're going to see more trading on company specifics. I bought a small position here and will add the dip if BMY heads south with the rest of the market next week.
NYSE:BMYLong
by ChristopherCarrollSmith
8
Healthcare probably going to take a hit this weekCongress's coronavirus stimulus deal reached Friday night included a provision requiring health insurers to bear the full cost of coronavirus test kits and to waive copays. The federal government will pay the cost for the uninsured. This will probably hurt health insurers Monday, though it might be good for service providers. Here's another piece of bad news: xenophobia related to the virus has angered the Chinese government, and China’s official newspaper Xinhua published a threat to cut off supply chains for the US pharmaceutical industry. If China followed through on this threat, there could be big US drug shortages, which would be bad for pharmaceutical and healthcare companies. The whole economy will be down this week due to expanding quarantines, new travel bans, and the failure of Trump's payroll tax cut proposal, but the healthcare sector may take extra damage Monday as it bears the brunt of the cost of coronavirus testing.
AMEX:XLVShort
by ChristopherCarrollSmith
4
BEAT- BEAST is about to be unleashed...Positional/swing tradeBEAT is your prototypical aggressive growth stock- Strong future growth potential with good earning and revenue track record ... If you can overlook its debt level. This beast was tamed for a while after its share price skyrocketed from $25 to almost $80 , but it is ready to unleash its fury again. But first, I think the pullback is in the store facing key resistance lvl in confluence with ichi and BB on the weekly timeframe. In addition, short % of float is around 10%. However, it is a bullish sign when price hovers below the key resistance lvl rather than experiencing outright price rejection. My buy zone is between $45 to $55 for the positional trade. The long term trendline and S/R flip below this price range will act as a strong support. Click the like button and follow me if you like my analysis :D
NASDAQ:BEAT
by Libratus
Biogen: Sell opportunity.BIIB closed the week around +25% as news regarding a crucial patent ruling came out in the company's favor. With the company's earnings also higher than the forecast, investors seem upbeat with the stock's dynamics. Even though the 1D chart turned overbought (RSI = 75.219, MACD = 6.690), on the weekly chart there is still a clear Resistance Zone at 370.00 - 389.00 which has been holding since 2016. The fact that the 1W candle pulled back making a big wick right after it entered the Resistance Zone, indicates that traders looked to book profits first. We see this as a strong sell opportunity towards at least the 267.00 Gap or even the 246.70 Symmetrical Support. ** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. ** Comments and likes are greatly appreciated.
NASDAQ:BIIBShort
by InvestingScope